VEGFR2/KDR/Flk-1 Antibody (4H3) [FITC]

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-18644F

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP1-18644F
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human

Applications

CyTOF-ready, ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Western Blot

Label

FITC (Excitation = 495 nm, Emission = 519 nm)

Antibody Source

Monoclonal Mouse IgG1 Clone # 4H3

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all VEGFR2/KDR/Flk-1 Antibodies »

Product Summary for VEGFR2/KDR/Flk-1 Antibody (4H3) [FITC]

Immunogen

Recombinant human soluble extracellular KDR (D7)

Specificity

The monoclonal antibody will detect native human VEGFR-2/KDR on the surface of different human cell types.

Marker

Endothelial Cell Marker

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Description

Clone # 3 changed to 4H3. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

Applications for VEGFR2/KDR/Flk-1 Antibody (4H3) [FITC]

Application
Recommended Usage

CyTOF-ready

Optimal dilutions of this antibody should be experimentally determined.

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: VEGFR2/KDR/Flk-1

Vascular endothelial growth factor receptor 2 (VEGFR2) is a member of a receptor tyrosine kinase family whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, cell proliferation, migration and differentiation. Like other common growth factor receptors, VEGF receptor 2 dimerises upon ligand binding and is autophosphorylated at multiple tyrosine residues. These sites can be involved in the regulation of kinase activity or can serve as binding sites for SH2 and phosphotyrosine binding containing signaling proteins. Phosphorylation of Tyrosines 1054 and 1059 in the activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosine kinase activity.

Defects in the VEGFR2 gene are associated with susceptibility to benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium called hemangioma capillary infantile. HCI is the most common tumor found in infants, found in up to 10% of all births.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Alternate Names

CD309, Flk-1, Flk1, KDR, KRD1, Ly73, VEGF R2

Gene Symbol

KDR

Additional VEGFR2/KDR/Flk-1 Products

Product Documents for VEGFR2/KDR/Flk-1 Antibody (4H3) [FITC]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for VEGFR2/KDR/Flk-1 Antibody (4H3) [FITC]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.